This site is intended for healthcare professionals
Drug information

Clindamycin Villerton 300 mg/50 ml solution for infusion

Read time: 15 mins
Last updated: 09 Sep 2020
Published: 09 Sep 2020

4.1 Therapeutic indications

Clindamycin is indicated for the treatment of the following severe infections caused by susceptible microorganisms (see section 5.1) in adults and adolescents older than 12 years:

- Staphylococcal bone and joint infections such as osteomyelitis and septic arthritis.

- Chronic sinusitis caused by anaerobic microorganisms.

- Infections of the lower respiratory tract such as:

• aspiration pneumonia, pulmonary abscess, necrotising pneumonia, and empyema.

In case of suspected polymicrobial pulmonary infections, an agent with adequate activity against Gram-negative bacteria should also be given in combination to cover possible Gram-negative bacteria.

- Complicated intra-abdominal infections such as peritonitis and abdominal abscess where the treatment of choice is clindamycin associated with an antibiotic with good activity against aerobic Gram-negative bacteria.

- Pelvic and female genital infections such as PID, endometritis, perivaginal infections, tubo-ovarian abscesses, salpingitis, pelvic cellulitis when simultaneously another antibiotic with good activity against aerobic Gram-negative bacteria is administered.

- Skin and soft tissue infections.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).